Collaborations are common in drug development. In most cases, the partners have similar goals — to develop and market a product — but their sensitivities around public disclosures about the collaboration may be very different. Join partners Timothy C. Atkins and Scott R. Jones as they discuss issues that may arise in connection with the disclosure obligations of collaboration partners.
Join us for an CLE Ethics presentation on Wednesday, December 6. This program will address how to identify your client and how the identity of your client affects the application of the attorney-client privilege to your confidential communications, waiver of the privilege, and the fate of those communications when the special committee has disbanded.